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AbstrACt
Objectives To quantify the relationship between home 
medicines review (HMR) receipt in older adults and 
sociodemographic, medication-related and health factors.
Design Prospective cohort analysis.
settings, participants, measurements Questionnaire 
data from a population-based cohort study of individuals 
aged ≥45 years, Sydney, Australia were linked with 
primary healthcare data, medication and hospitalisation 
data, to ascertain factors associated with HMR receipt 
during the period July 2009–June 2014. Medication-
related factors included exposure to five and more 
medications (polypharmacy), narrow therapeutic index 
medicines, potentially inappropriate prescribing defined 
using Beers Criteria medicines, and anticholinergic and 
sedative drugs, defined using the Drug Burden Index (DBI). 
Poisson and Cox regression models were used to evaluate 
HMR receipt in relation to sociodemographic, behavioural 
and health characteristics, and time-varying factors 
including medication use and hospitalisations.
Primary outcome HMR receipt during the 5-year study 
period.
results Over 5 years of follow-up, 4.7% (n=6115) of 
131 483 participants received at least one HMR. Five-year 
HMR receipt was: 1.5% in people using <5 medications 
at baseline, 6.8% with 5–9 medications, 12.7% with 
≥10 medications, 8.8% using Narrow Therapeutic 
Index medicines, 6.8% using Beers Criteria potentially 
inappropriate medicines and 7.4% using DBI medicines. 
Age-sex stratified HRs for HMR receipt were 6.07 (95% CI: 
5.58 to 6.59) and 12.46 (11.42 to 13.59) for concurrent 
use of 5–9 and ≥10 versus <5 medications, respectively. 
The age-sex adjusted rate ratio for HMR receipt was 2.65 
(2.51 to 2.80) with poor versus good self-reported health; 
this association was attenuated substantially following 
additional adjustment for polypharmacy.
Conclusions HMR was common in individuals using 
multiple medications, a formal indication for general 
practitioner referral and, to a lesser extent, with poorer 
health and other markers of high-risk prescribing. 
Despite this, HMR use over a 5-year period was generally 
below 10%, even in high-risk groups, suggesting 
substantial potential for improvement in uptake and 
targeting.
IntrODuCtIOn  
Adverse medication events are common 
in older adults and result in considerable 
morbidity and mortality.1–3 The home medi-
cines review (HMR), also referred to as 
domiciliary medication management review, 
is an Australian government-funded Medi-
care Benefits Schedule (MBS) service, subsi-
dised since 2001 with the aim of enhancing 
appropriate medicine use for community 
dwelling adults.4 5 This collaborative service 
involves patients, their general practitioner 
(GP) and pharmacist, whereby GPs refer 
their patients to an accredited pharmacist, 
who then conducts an interview with the 
patient and generates a written report for 
the GP, to support discussion of medication 
strengths and limitations of this study
 ► This study investigated prospectively the relation of 
home medicines review (HMR), which is conducted 
by an accredited pharmacist after referral from a 
general practitioner with the aim to promote qual-
ity use of medicines and reduce adverse medica-
tion events, to a range of previously uninvestigated 
factors using validated measures based on a large 
sample cohort.
 ► A series of time-varying analyses when updating 
medication exposure during the study period provid-
ed robust effect estimates of factors widely reported 
on HMR receipt.
 ► There is a caveat to the results’ interpretation in that 
influence by unmeasured factors such as precise 
daily dose and comorbidity burden has not been 
completely excluded.
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management plans with patients.5 At present, evidence 
regarding medication review in hospital, primary care 
and nursing home settings is limited, with some findings 
suggesting that HMR reviews are associated with reduc-
tions in certain adverse events and/or health services use 
related to medication use.6 7 Current evidence in Australia 
to support HMR services are based on demonstrated 
benefits of quality use of medicines8 and improved health 
outcomes.9 For example, individuals with heart failure 
who receive an HMR have a longer time to next hospital-
isation for heart failure than those who have not had an 
HMR.10 Furthermore, lower rates of warfarin associated 
bleeding and occurrence of medication-related adverse 
events in those receiving versus not receiving an HMR has 
been reported.11
Current recommendations advise that an HMR should 
be conducted among patients taking five or more medi-
cines (commonly termed polypharmacy), taking medica-
tions with a Narrow Therapeutic Index (NTI), attending 
different doctors, being recently discharged from 
hospital, having a culturally and linguistically diverse 
background and/or experiencing physical and cognitive 
difficulties managing their medication regimens.4 12 13 
Despite the quarterly forecast of 42 000 HMR services and 
an annual reimbursement of $175 million by 2020,14 data 
on who is receiving the services and whether or not they 
are being appropriately targeted in the general popula-
tion are not currently available. In particular, it is unclear 
whether HMRs are being targeted towards those people 
with markers of high-risk prescribing, especially among 
older adults, given the risks of widespread inappropriate 
medication use.1–3
Receiving an HMR appears to vary according to patient 
characteristics. Older men, and individuals from cultur-
ally and linguistically diverse backgrounds are less likely to 
receive an HMR than individuals without these character-
istics.4 Previous qualitative studies indicate that GPs’ knowl-
edge of HMR processes and time constraints may limit 
HMR uptake.15 16 In clients of the Australian Department of 
Veterans Affairs (DVA), HMR receipt was more common in 
females, individuals with dementia, heart failure, diabetes, 
lower socioeconomic status, higher number of medications 
and higher number of GP visits, and those who have been 
hospitalised, compared with other members of the popu-
lation.17 However, in spite of studies targeting pharmacists 
and GPs to improve HMR uptake,18 19 it is unclear if recom-
mendations in terms of HMR utilisation are being followed 
based on person-level data. Therefore, the aim of this study 
is to investigate factors in relation to HMR receipt in an older 
Australian cohort, focusing particularly on medication-re-




The Sax Institute’s 45 and Up Study is a population-based 
prospective cohort study comprising 267 153 participants 
in New South Wales (NSW).20 The 45 and Up Study 
participants comprising both middle aged and older 
adults, referred here as older adults, were randomly 
selected from the Department of Human Services enrol-
ment database and joined the study by completing a 
postal questionnaire distributed between 2006 and 2009. 
Participants provided consent for linkage of question-
naire data to a range of health data collections including 
the national MBS and Pharmaceutical Benefits Scheme 
(PBS) records, the NSW admitted patient data collec-
tion (APDC) and the NSW Register of Births, Deaths and 
Marriages (RBDM) records. The NSW Centre for Health 
Record Linkage provided the linked administrative data 
with false-positive rate of <0.5% and false-negative rate 
of <0.1%.21 Details of the study including the question-
naires, sampling frame and linkage methods have been 
described elsewhere.20–22
This study used the 45 and Up Study baseline question-
naire data linked to routinely collected data from a range 
of other sources, comprising information on sociodemo-
graphic characteristics, behavioural factors, self-reported 
health conditions (questionnaire); dispensing records 
of subsidised prescription medications (PBS), receipt 
of HMR (MBS), hospitalisations (APDC) and deaths 
(RBDM). In recognition of changing practice over time 
after the landmark HMR review in 2008,4 we set the 5-year 
period of observation for HMR receipt from 1 July 2009 
to 30 June 2014 to ensure that cohort members were 
followed over the same calendar period. We also defined 
an additional ‘baseline’ exposure period, covering the 
3 months immediately prior to the 5 year observation 
period (ie, the 3 months prior to 1 July 2009).
study population
PBS data provide complete medication dispensing 
records on those who hold healthcare concession cards.23 
PBS data on other population members, termed ‘general 
beneficiaries’ prior to April 2012 do not provide complete 
dispensing records as they only comprise dispensing 
records for medicines priced higher than the patient 
co-payment. Hence, we restricted the analysis to health-
care concession card holders based on PBS records to 
get a complete medication dispensing records. Among 
155 348 concessional beneficiaries recorded in the PBS 
data at any time during the study period, we excluded 
participants whose initial PBS-derived social security 
beneficiary status was non-concessional (n=20 077). We 
excluded another 16 participants as their PBS medica-
tion records were unclassifiable over the study period. 
Because HMR is only applicable to community-dwelling 
individuals, we further excluded those who self-reported 
as living in residential aged care facilities in the 45 and 
Up Study questionnaire (n=1106). Participants who held 
DVA healthcare cards were also excluded (n=2658), as 
PBS did not capture their subsidised prescription medica-
tion records. After exclusion of eight participants without 
any MBS records, the final study population comprised 
131 483 concession card holders (figure 1).
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We used the linked MBS records to determine the 
first occurrence of HMR during the 5-year period (item 
number: 900)12 which was set as yes or no. The MBS 
records available for these analyses included the date the 
HMR was conducted (the HMR service date); no data on 
the date that the patient was referred by their GP for the 
HMR were available. There may be up to 90 days from the 
date of referral to the date that the HMR is conducted 
by the pharmacist.13 Although medication use and other 
factors at the time of referral would most accurately 
reflect those on which the GP made the decision that an 
HMR was necessary, the exact date of HMR referral date 
was not available; hence, we used the HMR service date as 
the best available measure for analyses relating to time of 
HMR occurrence. However, this approach could allow a 
minor degree of reverse causality/measurement error to 
contribute to the results, for example, medication expo-
sure could possibly be influenced by the GP consultation 
when the referral for the HMR was made or use of medi-
cations could change for some other reason during the 
period between referral and HMR occurrence. There-
fore, we conducted a sensitivity analysis backdating the 
HMR occurrence by 90 days prior to the HMR service 
date, assuming that the real date when necessity of HMR 
was recommended is likely to fall within this 3-month 
period.13 We censored data if participants died, had 
markers of a residential aged care admission12 or their 
PBS beneficiary status became non-concessional, during 
the study period.
We used the Andersen-Newman model to classify 
self-reported characteristics potentially influencing 
receipt of HMR into three broad groups.24 Predisposing 
factors included age group in years (ie, 45–49, 50–54, 
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85 years and 
over); sex, as male or female; Language Other Than 
English (LOTE) spoken at home, as yes or no; marital 
status, as married/de facto or single; educational attain-
ment, as no school certificate, school certificate, trade or 
diploma, or degree or higher; smoking, as current, past 
or never; alcohol consumption, as 0 drinks, 1–14 drinks 
or ≥15 drinks per week; and body mass index (BMI) 
(kg/m2), as underweight (15 to <18.5), normal weight 
(18.5 to <25), overweight (25 to <30) or obese (≥30). 
Enabling factors included remoteness of residence using 
the postcode-based Accessibility Remoteness Index for 
Australia (ARIA+) scores,25 as metropolitan, regional or 
remote areas; annual household income, as <$A20 000, 
$A20 000–$A69 000 or ≥$A70 000; private health insur-
ance, as yes or no; and paid work status as yes or no. 
Health-need factors included functional limitation using the 
Figure 1 Study participants inclusion and exclusion. APDC, admitted patient data collection; ATC, Anatomic Therapeutic 
Chemical; DVA, Department of Veterans’ Affairs; MBS, Medicare Benefits Schedule; PBS, Pharmaceutical Benefits Scheme. 
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Table 1 Study population characteristics at July 2009
Characteristics*
Proportion (%) and number of medications in 
3 months prior to July 2009†
0–4 5–9 ≥10
Total 53.6 (70 537) 34.4 (45 283) 11.9 (15 663)
Age group (years)
  45–49 75.9 (4127) 18.5 (1006) 5.5 (301)
  50–54 70.4 (5135) 22.7 (1654) 7.0 (510)
  55–59 67.0 (8015) 24.9 (2976) 8.1 (970)
  60–64 65.2 (14 855) 26.9 (6129) 7.9 (1790)
  65–69 57.4 (16 132) 33.5 (9395) 9.1 (2555)
  70–74 47.7 (10 244) 39.3 (8447) 13.0 (2787)
  75–79 38.4 (5883) 43.8 (6709) 17.7 (2715)
  80–84 33.0 (4667) 46.8 (6612) 20.2 (2856)
  ≥85 29.5 (1479) 47.0 (2355) 23.5 (1179)
  Sex
  Male 54.4 (32 274) 34.4 (20 410) 11.3 (6683)
  Female 53.1 (38 263) 34.5 (24 873) 12.5 (8980)
Language Other Than 
English
  No 53.9 (63 799) 34.5 (40 815) 11.7 (13 853)
  Yes 51.8 (6738) 34.3 (4468) 13.9 (1810)
Marital status
  Partnered 55.9 (50 794) 33.4 (30 320) 10.7 (9734)
  Single 48.5 (19 318) 36.9 (14 676) 14.6 (5811)
Education
  No school certificate 43.2 (9898) 39.9 (9162) 16.9 (3874)
  School certificate 52.7 (25 286) 35.4 (16 982) 11.8 (5680)
  Trade or diploma 56.9 (23 099) 32.7 (13 278) 10.4 (4208)
  Degree or higher 64.2 (10 929) 27.7 (4709) 8.1 (1386)
Residence
  Metro 50.5 (27 255) 35.9 (19 370) 13.6 (7331)
  Regional 55.9 (41 872) 33.4 (25 022) 10.7 (8001)
  Remote 53.2 (1371) 34.2 (882) 12.6 (325)
Annual household 
income ($A)
  <20 000 45.3 (20 362) 39.2 (17 606) 15.4 (6937)
  20 000–69 999 61.1 (29 365) 30.7 (14 743) 8.2 (3944)
  ≥70 000 79.2 (4311) 17.1 (931) 3.7 (203)
Private insurance
  No 50.7 (32 144) 35.9 (22 778) 13.5 (8535)
  Yes 56.4 (38 390) 33.1 (22 502) 10.5 (7126)
Paid work
  No 47.4 (48 135) 38.5 (39 070) 14.2 (14 389)
  Yes 75.0 (22 402) 20.8 (6213) 4.3 (1274)
Smoking
  Never 55.9 (40 271) 33.5 (24 156) 10.5 (7585)
  Past 49.4 (24 302) 36.5 (17 988) 14.1 (6925)
  Current 58.7 (5742) 30.3 (2962) 11.0 (1074)
Alcohol drinks (per week)
  0 48.3 (24 636) 36.7 (18 719) 15.0 (7639)
  1–14 57.6 (34 838) 32.7 (19 749) 9.7 (5844)
  ≥15 58.1 (9412) 32.7 (5298) 9.2 (1486)
Continued
Characteristics*
Proportion (%) and number of medications in 
3 months prior to July 2009†
0–4 5–9 ≥10
BMI (kg/m2)
  Normal 61.4 (26 158) 29.9 (12 751) 8.7 (3728)
  Underweight 57.3 (1014) 31.1 (551) 11.6 (205)
  Overweight 54.5 (25 852) 34.8 (16 526) 10.7 (5082)
  Obese 42.5 (11 993) 39.8 (11 223) 17.7 (4994)
Physical functioning impairment
  No 78.3 (18 551) 19.2 (4541) 2.6 (608)
  Minor 68.1 (20 049) 27.7 (8152) 4.2 (1225)
  Moderate 47.9 (16 063) 41.0 (13 774) 11.1 (3721)
  Severe 25.8 (5748) 44.4 (9883) 29.8 (6633)
Psychological distress
  Low 59.7 (49 727) 32.0 (26 648) 8.4 (6968)
  Moderate 48.4 (8087) 35.9 (5999) 15.7 (2629)
  High 42.4 (4158) 36.7 (3602) 20.9 (2 045)
Hearing impairment
  No 57.1 (38 920) 32.6 (22 236) 10.3 (7039)
  Yes 50.1 (29 461) 36.4 (21 372) 13.5 (7936)
Memory impairment
  No 56.6 (55 783) 32.9 (32 431) 10.5 (10 311)
  Yes 44.4 (12 318) 39.3 (10 891) 16.3 (4 528)
Vision impairment
  No 56.7 (57 265) 33.2 (33 551) 10.1 (10 164)
  Yes 42.6 (10 618) 38.7 (9645) 18.6 (4640)
Self-reported cancers
  No 55.4 (58 706) 33.5 (35 460) 11.2 (11 819)
  Yes 46.4 (11 831) 38.5 (9823) 15.1 (3844)
Self-reported circulatory diseases
  No 60.1 (63 722) 31.2 (33 045) 8.7 (9242)
  Yes 26.8 (6815) 48.0 (12 238) 25.2 (6421)
Self-reported diabetes
  No 58.1 (67 131) 32.5 (37 495) 9.4 (10 866)
  Yes 21.3 (3406) 48.7 (7788) 30.0 (4797)
Self-reported poor health
  No 60.6 (61 630) 32.0 (32 552) 7.4 (7557)
  Yes 26.7 (6399) 43.7 (10 494) 29.6 (7104)
Beers Criteria list medicines †
  No 77.5 (50 898) 20.3 (13 347) 2.2 (1464)
  Yes 29.9 (19 639) 48.6 (31 936) 21.6 (14 199)
NTI medicines†‡ 
  No 60.4 (66 087) 31.7 (34 713) 7.9 (8595)
  Yes 20.2 (4450) 47.8 (10 570) 32.0 (7068)
Drug Burden Index medicines†
  No 70.3 (57 804) 25.9 (21 257) 3.8 (3119)
  Yes 25.8 (12 733) 48.7 (24 026) 25.4 (12 544)
Number of different doctors†
  ≤2 74.9 (40 580) 22.3 (12 061) 2.9 (1558)
  3 or 4 50.8 (18 328) 39.7 (14 313) 9.5 (3419)
  ≥5 28.2 (11 629) 45.9 (18 909) 25.9 (10 686)
Table 1 Continued 
Continued
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Medical Outcomes Study Physical Functioning scores,26 
as no (100), minor (90–99), moderate (60–89) or severe 
(0–59); psychological distress using the Kessler Psycho-
logical Distress Scale (K10) scores,27 as low (10–15), 
moderate (16–21) or high (22–50); hearing impairment, 
as yes (self-rated fair, poor hearing) or no (excellent, very 
good, good); vision impairment as yes (self-rated fair, 
poor vision) or no (excellent, very good, good); memory 
impairment, as yes (self-rated fair, poor memory) or no 
(excellent, very good, good); self-reported cancers, as yes 
or no; self-reported circulatory disease, as yes or no; self-re-
ported diabetes, as yes or no; self-reported poor health, 
as yes (self-rated fair, poor health) or no (excellent, very 
good, good). There were no missing data in age, sex or 
variables sourced from linked data. The proportion of 
missing data in other variables were: marital status (0.6%), 
education (2.3%), smoking (0.4%), alcohol (2.9%), 
BMI (8.7%), residence (0.0%), income (25.2%), insur-
ance (0.0%), physical functioning impairment (17.1%), 
psychological distress (16.4%), self-rated health (4.4%), 
hearing impairment (3.4%), memory impairment (4.0%) 
and vision impairment (4.3%). A separate category was 
included for missing values in regression models.
We used the linked PBS medication dispensing records 
to identify distinct medications based on the Anatomic 
Therapeutic Chemical classification codes.28 We esti-
mated monthly exposure to medicines by assuming date 
of dispensing plus 90 days as the duration of exposure 
for each medicine.29 30 Specifically, if the period of expo-
sure to a drug occurred in any month during the study 
period, the exposure of that drug was determined as 
yes. In this study, four markers of high-risk prescribing 
were considered including exposure to five and more 
medications (polypharmacy), NTI medicines, potentially 
inappropriate prescribing defined using Beers Criteria 
medicines, and anticholinergic and sedative drugs, 
defined using the Drug Burden Index (DBI).22 DBI and 
Beers drugs were developed for and have been studied 
in population groups aged 65 years and over. This age 
cut-off is unlikely to be absolute and DBI and Beers 
drugs may have clinical implications in vulnerable but 
younger population groups, such as people living with 
mental health conditions or cognitive impairment. To 
explore relations in younger groups, the current setting 
also included individuals aged 45–64 years, although the 
majority are over this age range. Given this, caution is 
necessary in the interpretation and generalisation of the 
DBI and Beers drugs for people in younger age groups.
We considered cohort baseline medicine exposure 
(exposure in the 3 months prior to 1 July 2009) to 
number of medications, categorised as using ≤4 drugs in 
every month, 5–9 drugs in any of the 3 months or ≥10 
drugs or hyperpolypharmacy in any of the 3 months31; 
and any use of the drugs with a high risk or NTI32 33 which 
were categorised as yes or no. Other than these medi-
cation-related indications for HMR, we also considered 
medicine exposures that were potentially inappropriate 
in older adults, including any use of the medicines on the 
2015 Beers criteria list of drugs independent of diseases34 
and exposure to medicines with clinically significant anti-
cholinergic and/or sedative effects based on the pharma-
cological risk assessment tool, DBI.35 Because PBS data 
do not provide actual daily dose information,36 exposure 
to DBI drugs was categorised as yes vs no, rather than 
imputing the daily dose actually taken by an individual 
participant.
This study used the linked hospitalisation data to iden-
tify recent hospitalisation during the 3 months prior to 1 
July 2009 (categorised as yes or no), and the MBS data 
to identify recipients of an HMR (categorised as yes or 
no during the previous immediate year) and number 
of different doctors visited during the 3 months prior 
to 1 July 2009 as the baseline exposures. Because most 
study participants received different dispensed medi-
cines at different time points during the study period, it 
is possible that more recent exposure may particularly 
impact on HMR receipt. We defined exposure to number 
of medications, medicines with NTI, medicines on the 
Beers Criteria and medicines included in the DBI as time-
varying factors based on whether or not participants were 
exposed to relevant medication-related factors during 
any of the 20 quarterly observational windows during the 
5-year study period. We also considered quarterly expo-
sure to hospitalised care based on hospitalisation records 
and number of different doctors based on MBS records, 
and therefore allowed participants to change relevant 
exposure status during the study period.
statistical analysis
We calculated the frequencies and proportions of partic-
ipants exposed to <5, 5–9 and 10 or more medications 
at baseline according to cohort characteristics. We also 
Characteristics*
Proportion (%) and number of medications in 
3 months prior to July 2009†
0–4 5–9 ≥10
Hospitalisation†
  No 54.1 (70 343) 34.4 (44 769) 11.5 (15 026)
  Yes 14.4 (194) 38.2 (514) 47.4 (637)
HMR (12 months prior)
  No 54.1 (70 409) 34.3 (44 637) 11.5 (15 022)
  Yes 9.0 (128) 45.7 (646) 45.3 (641)
*Missing categories were not presented.
†Data were presented as proportions (and numbers). We used the linked 
PBS data (April–June 2009), MBS data (April–June 2009) and APDC data 
(April–June 2009) to identify recent medication use, number of different 
doctors visited and recent hospitalisation during the 3 months prior to 1 July 
2009, respectively.
‡NTI drugs include digoxin, amiodarone, lignocaine, quinidine, flecainide, 
mexilitine, salicylate, perhexiline, theophylline, phenytoin, carbamazepine, 
sodium valproate, phenobarbitone, gentamicin, amikacin, vancomycin, 
lithium, warfarin, methotrexate, insulin, ciclosporin, levothyroxine, tacrolimus, 
bupropion, primidone, etravirine, enoxaparin, rivaroxaban, dabigatran, 
apixaban, cyclosproine, sirolimus, edoxaban, tobramycin and netilmicin.
APDC, admitted patient data collection; BMI, body mass index; HMR, 
home medicines review; MBS, Medicare Benefits Schedule; NTI, Narrow 
Therapeutic Index; PBS, Pharmaceutical Benefits Scheme.
Table 1 Continued 
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calculated the proportion of individuals having an HMR 
during the study period, and crude incidence rates as the 
number of people receiving at least one HMR per 1000 
person-years. We used Poisson regression models with 
robust error variance to estimate the rate ratios (RR) and 
95% CIs for HMR receipt in relation to individual factors, 
first adjusted for age and sex only, then further adjusted 
for the number of medications (ie, 0–4, 5–9, ≥10). We 
used Cox regression models with robust variance estimate 
to evaluate the HR for receiving an HMR as an approx-
imation to RR and 95% CI for time-varying medication 
and hospital care exposures, stratified by age and sex. We 
set p values <0.05 as statistically significant. We carried out 
all analyses using SAS V.9.4.
sensitivity analysis
We modelled the HMR receipt using backdated HMR 
occurrence (ie, HMR date of service minus 90 days) 
as the outcome variable to mimic the likely exposure 
scenario when requesting HMR, using binary categorisa-
tion for polypharmacy (ie, ≥5 medicines or fewer than 5). 
We compared the distribution of medication use between 
3 months before and after 1 July 2009, allowing for poten-
tial stockpiling when approaching end of financial year. 
The majority of participants included in these anal-
yses completed their questionnaires in 2008, meaning 
that the ‘baseline’ period over which the medication 
data were ascertained (3 months prior to 1 July 2009) 
was relatively close in time to the questionnaire-based 
reporting of their other characteristics. However, to test 
the possible impact of questionnaire data being further 
distant from the ‘baseline’ medication exposure ascer-
tainment we conducted sensitivity analyses excluding 
participants recruited before 2008. We also examined the 
effects on the main estimates of excluding participants 
with historical HMR receipt during July 2006–June 2009, 
and excluding participants aged <65 years at the baseline 
because Beers criteria and DBI measures were developed 
for older olds, respectively.
Community and participant involvement
Participants in the 45 and Up Study receive an annual 
newsletter informing them of the study progress and proj-
ects under way using the study data. The study website 
is also kept up to date regarding research under way 
and events. There is no individual feedback to study 
participants regarding findings or results specific to that 
individual.
results
A total of 131 483 participants who were concession card 
holders were eligible for this study (figure 1). The median 
age was 68.1 (IQR 13.4) years and less than half (45.2%, 
n=59 367) were men. Figure 2 presents the distribution 
of monthly numbers of medications at baseline (ie, aver-
aged over the 3 months immediately prior to July 2009) 
in the cohort. Overall, 53.6% (n=70 537) of the cohort 
used fewer than five medications, 34.4% (n=45 283) used 
5–9 medications and 11.9% (n=15 663) used 10 or more 
drugs (termed ‘hyperpolypharmacy’) (table 1). At base-
line 17% study participants were using NTI medications, 
and 37% and 50% using medications contributing to 
DBI and Beers criteria, respectively. The distribution of 
health factors varied among participants using different 
numbers of medications, with participants experiencing 
greater morbidity concomitantly using more medicines 
(table 1).
Population characteristics
During the study period from July 2009 to June 2014, 
4.7% (n=6115) of the study cohort received at least one 
HMR. The proportions receiving at least one HMR during 
follow-up were 1.5% (1065/70 537) of those using fewer 
than five medications monthly at baseline, 6.8% (3068/45 
283) using 5–9 medications, 12.7% (1982/15 663) using 
10 or more medications, 8.8% (1941/22 088) of those 
exposed to medicines with NTI, 6.8% (4461/65 774) to 
potentially inappropriate medications defined using the 
Beers Criteria and 7.4% (3648/49 303) of those exposed 
to medicines included in the DBI pharmacological tool.
The HMR incidence rate increased with age (table 2). 
After adjustment for age and sex, HMR receipt was 
strongly associated with taking 5–9 medications, a formal 
indication for referral (adjusted RR: 4.94; 95% CI: 4.60 to 
5.30) and 10 or more medications (adjusted RR: 10.71; 
95% CI: 9.91 to 11.57) compared with <5 medications 
(table 2). Increased HMR receipt was also observed in 
older people, smokers, those who were single, obese, 
without private insurance, not in paid work, residing 
remotely, having morbidity such as diabetes and broader 
health issues such as impaired physical functioning, 
compared with other study participants. HMR receipt 
did not vary significantly between males and females, 
Figure 2 Monthly numbers of unique drugs averaged over a 
3-month period immediately prior to July 2009.
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Table 2 Prospective relationship of HMR to factors of interest
Cohort characteristics
Receiving at least one HMR Rate ratios (95% CI)
Proportion (%) (n/
persons)
Crude rate (per 1000) (n/
person-years*)
Adjusted for age and sex, 
where appropriate
Adjusted for age, sex and 
number of medication
Age group (years)
  45–49 2.2 (121/5434) 5.2 (121/23 396) 1.00 1.00
  50–54 3.2 (232/7299) 7.2 (232/32 079) 1.40 (1.12 to 1.74) 1.23 (0.99 to 1.53)
  55–59 3.8 (456/11 961) 8.4 (456/54 251) 1.63 (1.33 to 1.99) 1.34 (1.10 to 1.63)
  60–64 4.3 (975/22 774) 9.2 (975/105 553) 1.79 (1.48 to 2.16) 1.44 (1.19 to 1.74)
  65–69 5.3 (1500/28 082) 11.7 (1500/128 440) 2.27 (1.89 to 2.73) 1.61 (1.34 to 1.93)
  70–74 4.9 (1042/21 478) 13.8 (1042/75 532) 2.69 (2.23 to 3.24) 1.62 (1.34 to 1.96)
  75–79 5.2 (801/15 307) 18.5 (801/43 221) 3.61 (2.98 to 4.37) 1.84 (1.52 to 2.23)
  80–84 5.3 (753/14 135) 20.7 (753/36 461) 4.02 (3.32 to 4.87) 1.92 (1.59 to 2.33)
  ≥85 4.7 (235/5013) 21.7 (235/10 850) 4.19 (3.37 to 5.22) 1.90 (1.53 to 2.37)
Sex
  Male 4.6 (2757/59 367) 12.3 (2757/224 506) 1.00 1.00
  Female 4.7 (3358/72 116) 11.8 (3358/285 277) 1.04 (0.99 to 1.09) 0.95 (0.90 to 1.00)
LOTE
  No 4.6 (5462/118 467) 11.9 (5462/458 594) 1.00 1.00
  Yes 5.0 (653/13 016) 12.8 (653/51 189) 1.08 (0.99 to 1.17) 1.00 (0.92 to 1.08)
Marital status
  Partnered 4.5 (4069/90 848) 11.3 (4069/359 762) 1.00 1.00
  Single 5.0 (1986/39 805) 13.5 (1986/146 910) 1.15 (1.09 to 1.22) 1.06 (1.00 to 1.12)
Education
  No school certificate 6.5 (1498/22 934) 17.5 (1498/85 812) 1.00 1.00
  School certificate 4.7 (2231/47 948) 11.9 (2231/186 788) 0.70 (0.66 to 0.75) 0.82 (0.77 to 0.88)
  Trade or diploma 4.2 (1702/40 585) 10.7 (1702/158 610) 0.63 (0.59 to 0.68) 0.78 (0.73 to 0.84)
  Degree or higher 2.8 (485/17 024) 7.1 (485/68 438) 0.42 (0.38 to 0.47) 0.59 (0.53 to 0.66)
Residence
  Metro 4.4 (2383/53 956) 11.8 (2383/202 633) 1.00 1.00
  Regional 4.8 (3579/74 895) 12.1 (3579/296 995) 1.13 (1.07 to 1.19) 1.19 (1.13 to 1.25)
  Remote 5.9 (153/2578) 15.4 (153/9917) 1.51 (1.28 to 1.78) 1.43 (1.22 to 1.69)
Income ($)
  <20 000 5.8 (2590/44 905) 15.4 (2590/168 773) 1.00 1.00
  20 000–69 999 3.5 (1672/48 052) 8.6 (1672/194 231) 0.59 (0.56 to 0.63) 0.75 (0.71 to 0.80)
  ≥70 000 1.5 (79/5445) 3.4 (79/23 027) 0.26 (0.21 to 0.33) 0.45 (0.36 to 0.56)
Private insurance
  No 5.5 (3519/63 457) 14.4 (3519/245 192) 1.00 1.00
  Yes 3.8 (2594/68 018) 9.8 (2594/264 563) 0.64 (0.61 to 0.68) 0.74 (0.71 to 0.78)
Paid work
  No 5.4 (5447/101 594) 14.3 (5447/380 392) 1.00 1.00
  Yes 2.2 (668/29 889) 5.2 (668/129 390) 0.44 (0.40 to 0.48) 0.65 (0.59 to 0.70)
Smoking
  Never 4.2 (3001/72 012) 10.8 (3001/278 403) 1.00 1.00
  Past 5.2 (2565/49 215) 13.6 (2565/188 718) 1.31 (1.24 to 1.39) 1.11 (1.05 to 1.17)
  Current 5.4 (525/9778) 12.9 (525/40 836) 1.62 (1.47 to 1.78) 1.37 (1.24 to 1.50)
Alcohol drinks (per week)
  0 5.5 (2791/50 994) 14.4 (2791/194 393) 1.00 1.00
  1–14 4.0 (2438/60 431) 10.3 (2438/236 441) 0.71 (0.67 to 0.75) 0.84 (0.80 to 0.89)
Continued
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Cohort characteristics
Receiving at least one HMR Rate ratios (95% CI)
Proportion (%) (n/
persons)
Crude rate (per 1000) (n/
person-years*)
Adjusted for age and sex, 
where appropriate
Adjusted for age, sex and 
number of medication
  ≥15 3.9 (632/16 196) 9.7 (632/65 058) 0.69 (0.63 to 0.75) 0.79 (0.72 to 0.86)
BMI
  Normal 3.2 (1357/42 637) 8.3 (1 357/162 703) 1.00 1.00
  Underweight 3.4 (61/1770) 9.9 (61/6187) 1.17 (0.90 to 1.51) 1.13 (0.88 to 1.47)
  Overweight 4.3 (2031/47 460) 10.9 (2031/185 725) 1.35 (1.26 to 1.45) 1.14 (1.06 to 1.22)
  Obese 7.1 (2014/28 210) 17.8 (2,014/113 120) 2.43 (2.27 to 2.61) 1.54 (1.44 to 1.66)
Physical functioning impairment
  No 2.0 (469/23 700) 4.6 (469/102 566) 1.00 1.00
  Minor 2.9 (852/29 426) 7.0 (852/120 968) 1.40 (1.25 to 1.56) 1.20 (1.07 to 1.34)
  Moderate 4.9 (1654/33 558) 12.9 (1654/128 662) 2.49 (2.24 to 2.76) 1.54 (1.39 to 1.71)
  Severe 8.3 (1852/22 264) 24.1 (1852/77 021) 4.81 (4.34 to 5.33) 2.02 (1.81 to 2.24)
Psychological distress
  Low 3.7 (3085/83 343) 9.3 (3085/331 167) 1.00 1.00
  Moderate 5.5 (926/16 715) 14.1 (926/65 746) 1.71 (1.59 to 1.84) 1.26 (1.17 to 1.35)
  High 7.2 (706/9805) 17.9 (706/39 347) 2.52 (2.32 to 2.73) 1.52 (1.39 to 1.65)
Hearing impairment
  No 4.2 (2844/68 195) 10.4 (2844/274 278) 1.00 1.00
  Yes 5.2 (3028/58 769) 13.8 (3028/218 928) 1.23 (1.17 to 1.30) 1.13 (1.07 to 1.19)
Memory impairment
  No 4.2 (4100/98 525) 10.5 (4100/389 703) 1.00 1.00
  Yes 6.1 (1702/27 737) 16.9 (1702/100 963) 1.58 (1.49 to 1.67) 1.29 (1.21 to 1.36)
Vision impairment
  No 4.2 (4252/100 980) 10.7 (4252/397 466) 1.00 1.00
  Yes 6.1 (1511/24 903) 16.5 (1511/91 761) 1.56 (1.47 to 1.65) 1.19 (1.12 to 1.27)
Self-reported cancer
  No 4.6 (4864/105 985) 11.6 (4864/417 802) 1.00 1.00
  Yes 4.9 (1251/25 498) 13.6 (1251/91 980) 1.06 (1.00 to 1.13) 0.97 (0.91 to 1.03)
Self-reported circulatory disease
  No 3.9 (4097/106 009) 9.7 (4097/423 249) 1.00 1.00
  Yes 7.9 (2018/25 474) 23.3 (2018/86 533) 2.14 (2.02 to 2.26) 1.31 (1.24 to 1.39)
Self-reported diabetes
  No 3.9 (4491/115 492) 9.9 (4491/452 561) 1.00 1.00
  Yes 10.2 (1624/15 991) 28.4 (1624/57 222) 2.76 (2.61 to 2.92) 1.53 (1.44 to 1.63)
Self-reported poor health
  No 3.7 (3731/101 739) 9.2 (3731/404 098) 1.00 1.00
  Yes 8.4 (2011/23 997) 23.6 (2011/85 176) 2.65 (2.51 to 2.80) 1.43 (1.35 to 1.52)
Number of medications†
  0–4 1.5 (1065/70 537) 3.6 (1065/298 042) 1.00 Not applicable
  5–9 6.8 (3068/45 283) 18.8 (3068/163 611) 4.94 (4.60 to 5.30) Not applicable
  ≥10 12.7 (1982/15 663) 41.2 (1982/48 130) 10.71 (9.91 to 11.57) Not applicable
Beers Criteria list medicines†
  No 2.5 (1654/65 709) 6.2 (1654/268 836) 1.00 1.00
  Yes 6.8 (4461/65 774) 18.5 (4461/240 946) 2.82 (2.66 to 2.99) 1.23 (1.16 to 1.32)
Narrow Therapeutic Index medicines†
  No 3.8 (4174/109 395) 9.6 (4174/434 687) 1.00 1.00
  Yes 8.8 (1941/22 088) 25.8 (1941/75 096) 2.46 (2.32 to 2.60) 1.33 (1.26 to 1.41)
Table 2 Continued 
Continued
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or among persons with different language backgrounds 
(table 2).
Further adjustment for number of medications substan-
tially attenuated the observed age-sex adjusted associ-
ation between HMR receipt and sociodemographic, 
behavioural and health-need factors (table 2). Having an 
HMR during 12 months prior to cohort baseline remained 
strongly associated with the HMR occurrence during the 
study period (table 2).
time-varying factors
Considering time-varying factors specifically, HMR was 
more likely to occur in the study participants: dispensed 
greater numbers of medications; and dispensed medi-
cines with NTI, in the Beers Criteria List or DBI; visiting 
greater number of different doctors; or being recently 
discharged from hospital, over time (table 3). Sensitivity 
analysis using backdated HMR receipt as the outcome 
variable demonstrated similar findings, except that recent 
hospitalisation was not significantly associated with subse-
quent HMR receipt (table 3). Further sensitivity analysis 
did not materially alter the main results (online supple-
mentary table 1).
DIsCussIOn
In this population-based prospective study, HMR receipt 
in older adults was higher in those who had character-
istics consistent with high-risk medication use, partic-
ularly greater numbers of medications. Classes of 
medicines that are implicated in medication-related 
problems, including medicines with a NTI—(which are 
an indication for HMR) and medicines in the Beers 
Criteria or included in the DBI—(which are not formal 
indications for HMR) indicated an approximate twofold 
increase in HMR receipt, which were not strongly inde-
pendently associated with HMR receipt, after adjustment 
for number of medications. Despite higher HMR use in 
those with polypharmacy and other markers of high-risk 
prescribing, over 90% of older adults with these markers 
did not receive an HMR over a 5-year period; an HMR 
was received by 8.3% of participants dispensed ≥5 medi-
cations, 6.8% using Beers drugs, 8.8% using NTI drugs 
and 7.4% using DBI drugs.
The finding of a sevenfold higher HMR receipt in those 
with polypharmacy versus without polypharmacy provides 
novel population-based evidence that the HMR is, to some 
extent, being targeted. It is compatible with the finding of 
7% increase (relative risk: 1.07, 95% CI: 1.06 to 1.07) with 
the number of unique medications based on a veteran 
cohort in Australia which used a static approach adjusting 
for number of medications used in the year prior to the 
index date in a continuous scale.17 Differences in the defi-
nition and adjustment for number of medications may 
partly explain the larger relative effect estimates in the 
present analysis.
We also found a range of comorbid conditions were 
associated with increased HMR receipt, consistent with 
previous findings that HMR receipt increased among 
Australian veterans with dementia, heart failure and 
diabetes; and those with lower socioeconomic status.17 
Factors widely reported to be associated with increased 
healthcare utilisation, such as rural/remote residence, 
Cohort characteristics
Receiving at least one HMR Rate ratios (95% CI)
Proportion (%) (n/
persons)
Crude rate (per 1000) (n/
person-years*)
Adjusted for age and sex, 
where appropriate
Adjusted for age, sex and 
number of medication
Drug Burden Index medicines†
  No 3.0 (2467/82 180) 7.4 (2467/332 105) 1.00 1.00
  Yes 7.4 (3648/49 303) 20.5 (3648/177 677) 2.69 (2.55 to 2.83) 1.27 (1.20 to 1.35)
Number of different doctors†
  ≤2 2.4 (1285/54 199) 5.6 (1285/227 696) 1.00 1.00
  3 or 4 4.8 (1740/36 060) 12.6 (1740/138 610) 2.08 (1.94 to 2.24) 1.41 (1.30 to 1.51)
  ≥5 7.5 (3090/41 224) 21.5 (3090/143 476) 3.44 (3.21 to 3.67) 1.60 (1.49 to 1.72)
Hospitalisation†
  No 4.6 (6013/130 138) 11.9 (6013/506 066) 1.00 1.00
  Yes 7.6 (102/1345) 27.4 (102/3717) 1.97 (1.62 to 2.40) 1.05 (0.86 to 1.28)
HMR (12 months prior)
  No 4.3 (5573/130 068) 11.0 (5573/506 705) 1.00 1.00
  Yes 38.3 (542/1415) 176.1 (542/3078) 13.56 (12.36 to 14.86) 7.23 (6.57 to 7.96)
*Total person-years were rounded to the nearest integer.
†We used the linked PBS data (April–June 2009), MBS data (April–June 2009) and APDC data (April–June 2009) to identify recent medication 
use, number of different doctors visited and recent hospitalisation during the 3 months prior to 1 July 2009, respectively.
APDC, admitted patient data collection; BMI, body mass index; HMR, home medicines review; LOTE, Language Other Than English; MBS, 
Medicare Benefits Schedule; PBS, Pharmaceutical Benefits Scheme. 
Table 2 Continued 
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Table 3 Time-varying exposures for HMR HR and its 95% CI
Time-varying drug exposure HR (95% CI)*
Number of medications All Male Female
0–4 1.00 1.00 1.00
5–9 6.07 (5.58 to 6.59) 5.49 (4.87 to 6.18) 6.66 (5.92 to 7.48)
≥10 12.46 (11.42 to 13.59) 11.18 (9.88 to 12.66) 13.75 (12.17 to 15.54)
Polypharmacy
  None (<5 drugs) 1.00 1.00 1.00
  Yes (≥5 drugs) 7.76 (7.16 to 8.41) 6.99 (6.24 to7.83) 8.54 (7.62 to 9.57)
Beers drugs
  No 1.00 1.00 1.00
  Yes 2.91 (2.74 to 3.09) 2.66 (2.44 to 2.89) 3.18 (2.92 to 3.47)
NTI drugs
  No 1.00 1.00 1.00
  Yes 2.32 (2.20 to 2.45) 2.55 (2.35 to 2.76) 2.16 (2.00 to 2.31)
DBI drugs
  No 1.00 1.00 1.00
  Yes 2.67 (2.53 to 2.81) 2.45 (2.27 to 2.64) 2.88 (2.68 to 3.10)
Hospitalisations
  No 1.00 1.00 1.00
  Yes 1.34 (1.11 to 1.61) 1.52 (1.19 to 1.94) 1.15 (0.87 to 1.52)
Number of different doctors
  ≤2 1.00 1.00 1.00
  3 or 4 3.04 (2.82 to 3.28) 2.91 (2.60 to 3.26) 3.15 (2.85 to 3.48)
  ≥5 5.41 (5.04 to 5.82) 5.37 (4.83 to 5.98) 5.44 (4.94 to 5.99)
Sensitivity analysis for HMR dated back 90 days based on date of service
  Number of medications All Male Female
  0–4 1.00 1.00 1.00
  5–9 3.18 (2.97 to 3.40) 3.10 (2.81 to 3.42) 3.25 (2.96 to 3.57)
  ≥10 5.80 (5.39 to 6.24) 5.83 (5.24 to 6.48) 5.78 (5.23 to 6.40)
  Polypharmacy
  None (<5 drugs) 1.00 1.00 1.00
  Yes (≥5 drugs) 3.88 (3.64 to 4.14) 3.82 (3.49 to 4.19) 3.93 (3.60 to 4.29)
  Beers Criteria list medicines
  No 1.00 1.00 1.00
  Yes 1.97 (1.87 to 2.08) 1.89 (1.75 to 2.04) 2.05 (1.90 to 2.21)
NTI medicines
  No 1.00 1.00 1.00
  Yes 1.87 (1.77 to 1.97) 2.06 (1.91 to 2.23) 1.72 (1.60 to 1.85)
DBI medicines
  No 1.00 1.00 1.00
  Yes 1.99 (1.90 to 2.09) 1.90 (1.77 to 2.05) 2.08 (1.94 to 2.22)
Hospitalisations
  No 1.00 1.00 1.00
  Yes 0.98 (0.80 to 1.20) 0.83 (0.61 to 1.13) 1.13 (0.87 to 1.48)
Number of different doctors
  ≤2 1.00 1.00 1.00
Continued
 on 24 F









pen: first published as 10.1136/bm





11Du W, et al. BMJ Open 2019;9:e027305. doi:10.1136/bmjopen-2018-027305
Open access
lower educational attainment and lower household 
income were also associated with increased HMR receipt. 
Since these groups are also at increased risk of certain 
relevant health problems, this potentially reflects appro-
priate prioritisation by GPs assessing the need for HMR 
services.5 Although poorer health functioning and/
or reduced access to healthcare would be expected to 
have considerable independent relevance to medication 
safety, their relationship to HMR receipt in the current 
cohort was largely explained by the number of medica-
tions; however, these factors are difficult to quantify sepa-
rately. Population subgroups at risk of adverse medication 
events could be considered to be at greater need than 
others for an HMR, including older males and individuals 
from culturally and linguistically diverse backgrounds.4 
There was no difference in HMR receipt among males 
and participants with a LOTE background compared 
with other cohort members. These findings appear to 
differ from some previous findings.4 17 Nevertheless, the 
findings emphasise the need to continue efforts to reach 
targeted population subgroups, including those experi-
encing high-risk prescribing.
Although the optimal use of the HMR is unknown, the 
overall HMR coverage of 4.7% in the study population 
of concession-card holders and particularly the 8.3% in 
those taking five and more medications appears low, espe-
cially as it is recommended in the latter group. Through 
almost a decade since the landmark qualitative review 
of HMR conducted in 2008,4 much attention has been 
given to increasing HMR use. Previous studies reported 
HMR constraints from GPs’, pharmacists’ and patients’ 
perspectives, including limited resources, limited time, 
low health literacy and low awareness.4 15 16 Several 
changes have been made to facilitate HMR services such as 
allowing GPs to refer HMR services directly to an accred-
ited pharmacist to enhance GP-pharmacist communi-
cation.37 However, few patient-centred strategies have 
been attempted. Sustained commitment and initiatives to 
empower GPs, pharmacists and patients in particular, may 
have the potential to increase HMR receipt and maximise 
its benefits.
Current recommendations also encourage HMR 
for patients recently discharged from hospital.12 13 We 
found a significant 34% higher HMR receipt (HR: 1.34; 
95% CI: 1.11 to 1.61) in association with recent hospital 
care in older Australians, which is not inconsistent with 
the previous finding of 9% increase (relative risk: 1.09; 
95% CI: 1.04 to 1.16) among veterans having an annual 1–2 
hospitalisations compared with those having no hospital-
isation.17 In the sensitivity analysis using backdated HMR 
receipt to account for the possible different medication 
exposure scenario between requesting and undertaking 
HMR, we did not find a statistically significant association 
between recent hospital care and increased HMR receipt.
This study had a large sample size and was able to inves-
tigate prospectively a large number of factors using vali-
dated measures. Findings include the relation of HMR to 
a range of previously uninvestigated factors and provide 
more robust evidence on results which were largely consis-
tent with previous studies. We were also able to account for 
a range of different health-need factors and to consider 
to what extent observed relationships were explained by 
the strong relation of HMR to polypharmacy. For missing 
values of some confounding factors, we neither attempted 
to conduct complete analysis nor multiple imputations 
without knowledge of the missingness mechanisms. A 
separate missing category was modelled in the RR estima-
tion without reduction in sample size and statistical effi-
ciency, and these variables with missing values were not 
considered in the Cox regression models. Although bias 
due to measurement errors was deemed minimal, appro-
priate care should be given to interpreting results. The 
observed associations with different medication factors 
were robust and did not change materially after a series of 
sensitivity analyses, in particular when updating medica-
tion exposure during the study period. A limitation of this 
study is that we lack complete information which GPs used 
to assess the HMR needs of their patients, for example, 
precise daily dose information, adherence to medications 
and adverse symptoms and signs in relation to medicines. 
The consistency of findings across different medication-re-
lated factors and following sensitivity analyses indicate that 
these unmeasured factors are unlikely to overly influence 
the observed results, although this possibility cannot be 
excluded completely. Absolute proportions of individ-
uals receiving HMR should be interpreted with caution 
because our study population of concession card holders 
is not directly representative of the general population; 
given the relative disadvantage and increased morbidity 
in this group, the observed proportions receiving an HMR 
may, if anything, be higher than in the general population. 
Moreover, observed relative risks are likely to be reliable.38
Time-varying drug exposure HR (95% CI)*
Number of medications All Male Female
  3 or 4 2.54 (2.37 to 2.72) 2.40 (2.16 to 2.66) 2.66 (2.42 to 2.92)
  ≥5 4.36 (4.09 to 4.66) 4.36 (3.96 to 4.81) 4.36 (3.99 to 4.77)
*HR was estimated for the entire study population (n=131 483) and stratified by age and/or sex controlling for listed time-varying medication 
and hospital care exposures only.
DBI, Drug Burden Index; HMR, home medicines review; NTI, Narrow Therapeutic Index.
Table 3 Continued 
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The study findings provide new evidence on factors 
associated with HMR and are likely to inform approaches 
to improve HMR service to reach patients of greater 
need. Although it is evident that increased HMR receipt 
among older adults has largely occurred among those 
with polypharmacy, the majority of older adults with 
polypharmacy and prescribed high-risk medicines have 
not had an HMR. Continuing efforts are warranted to 
extend its delivery to patients of greater need. Given 
the important role of HMR in Australian healthcare 
services, future research should also target its effec-
tiveness in reducing high-risk prescribing and relevant 
health outcomes.
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